PAT-1251

DB16735InvestigationalSmall molecule

PAT-1251 is under investigation in clinical trial NCT04054245 (PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocytosis Myelofibrosis).

Mechanism: Pharmacologically active on Lysyl oxidase homolog 2
Curator reviewed
Formula / weight: C₁₈H₁₇F₄N₃O₃ · 399.346 g/mol (avg)
Code names: PAT-1251

Resolves to

Compound

UNIIY3HMF6G24BCAS2098884-52-5ChEMBLCHEMBL4116649

Structure

InChIKeyODGXXYXJORZPHE-ZIAGYGMSSA-NSMILESNCC1=CC(=NC(OC2=CC(=CC=C2)C(=O)N2C[C@@H](O)[C@H](F)C2)=C1)C(F)(F)F

Targets

Q9Y4K0LOXL2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with PAT-1251, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account